Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.

Treatment Combinations for Alzheimer’s Disease: Current and Future Pharmacotherapy Options

Open access
Cummings, Jeffrey L., Tong, Gary, Ballard, Clive · 2019 · Journal of Alzheimer's Disease

Abstract

Although Alzheimer's disease (AD) is the world's leading cause of dementia and the population of patients with AD continues to grow, no new therapies have been approved in more than a decade. Many clinical trials of single-agent therapies have failed to affect disease progression or symptoms compared with placebo. The complex pathophysiology of AD may necessitate combination treatments rather than monotherapy. The goal of this narrative literature review is to describe types of combination therapy, review the current clinical evidence for combination therapy regimens (both symptomatic and disease-modifying) in the treatment of AD, describe innovative clinical trial study designs that may be effective in testing combination therapy, and discuss the regulatory and drug development landscape for combination therapy. Successful combination therapies in other complex disorders, such as human immunodeficiency virus, may provide useful examples of a potential path forward for AD treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3233/jad-180766

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig.1 Combination therapies in the AD drug development pipeline. 5-HT, 5-hydroxytryptamine (serotonin); Aβ, amyloid-β; AChE1, acetylcholinesterase inhibitor; AD, Alzheimer’s disease; BACE, aspartyl protease β-site amyloid precursor protein cleaving enzyme; GM-CSF, granulocyte-macrophage colony-stimulating factor; MAO, monoamine oxidase; NMDA, N-methyl-D-aspartate; PPAR, peroxisome-proliferator activated receptor; RAGE, receptor for advanced glycation end-products; rTMS, repetitive transcranial magnetic stimulation.
Fig.1 Combination therapies in the AD drug development pipeline. 5-HT, 5-hydroxytryptamine (serotonin); Aβ, amyloid-β; AChE1, acetylcholinesterase inhibitor; AD, Alzheimer’s disease; BACE, aspartyl protease β-site amyloid precursor protein cleaving enzyme; GM-CSF, granulocyte-macrophage colony-stimulating factor; MAO, monoamine oxidase; NMDA, N-methyl-D-aspartate; PPAR, peroxisome-proliferator activated receptor; RAGE, receptor for advanced glycation end-products; rTMS, repetitive transcranial magnetic stimulation.CC BY-NC · PubMed Central
Fig.2 Combination drug development.
Fig.2 Combination drug development.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

4 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 61 references

Research works printed but not linked: 1

  1. Cummings, 2008, Effect of cholinesterase inhibitors on behavior, Neurobiol Aging, 29, S6

Cited by

See all 588

Metadata

Authors
Cummings, J. L., Tong, G., & Ballard, C.
Affiliations
  • Cleveland Clinic (US)
  • Lundbeck (United States) (US)
  • University of Exeter (GB)
Corresponding author
Cummings, Jeffrey L.
Venue
Journal of Alzheimer's Disease
Published
2019-02-12
Volume
67
Issue
3
Pages
779-794
ISSN
  • 1387-2877 (ISSN-L)
  • 1875-8908
OpenAlex
W2913000824
Cited by
588
References
61
Citations by year
2026: 45 · 2025: 92 · 2024: 90 · 2023: 113 · 2022: 110 · 2021: 81 · 2020: 42 · 2019: 13
FWCI
7.35
Type
journal article
Language
en
Open access
Locations
  • Journal of Alzheimer s Disease (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Digital Scholarship - UNLV (University of Nevada Reno) (submittedVersion, cc-by-nc)
  • Royal Devon and Exeter Research Repository (Royal Devon and Exeter) (submittedVersion, cc-by-nc)
Funders
  • H. Lundbeck A/S (P20GM109025)
  • National Institutes of Health
  • National Institute of General Medical Sciences (P20GM109025)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords
Alzheimer's disease, combination therapy
MeSH terms
Alzheimer Disease, Drug Therapy, Combination, Humans, Nootropic Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treatment Combinations for Alzheimer’s Disease: Current and Future Pharmacotherapy Options. https://app.cochat.ai/papers/10.3233/jad-180766
The paper
Cummings, J. L., Tong, G., & Ballard, C. (2019). Treatment Combinations for Alzheimer’s Disease: Current and Future Pharmacotherapy Options. Journal of Alzheimer's Disease. https://doi.org/10.3233/jad-180766

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.